Industry Perspective on the Medical Risk of Visible Particles in Injectable Drug Products

References

1. 1.↵
   Injectable Drug Delivery: Probing the Route to Growth. Datamonitor, January 2004. http://www.datamonitor.com/Products/Free/Report/DMHC1964/010DMHC1964.pdf (accessed July 9, 2014).
2. 2.↵
   General Chapter <790> Visible Particulates in Injections. USP 37/NF 32; U.S. Pharmacopeia: 2014. www.usp.org.
3. 3.↵
   1. Lynn S.

   Drug Defects. Presented at the 37th International Good Manufacturing Practices Conference. Mar 14, 2013, Athens, GA.
4. 4.↵
   EudraLex, Inspections. An Analysis of Quality Product Defects in the Centralised Procedure; European Commission: 2007. http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2009/10/WC500004420.pdf (accessed July 9, 2014).
5. 5.↵
   EudraLex, Standard Operating Procedure—Annex 4, Crisis Management Regarding Defects of Centrally Authorised Products: Classification of Batch Recalls for Quality Defects; European Commission: 2012. http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2009/10/WC500004404.pdf (accessed June 30, 2014).
6. 6.↵
   MHRA Drug Alerts website. http://www.mhra.gov.uk/Publications/Safetywarnings/DrugAlerts/index.htm (accessed June 30, 2014).
7. 7.↵
   MHRA Publications and Consultations, Safety Warnings, Drug Alerts. Class 2 Medicines Recall (action within 48 hours): Fybogel Hi-Fibre and Fybogel Orange manufactured by Reckitt Benckiser Healthcare (UK) Limited (EL (14)A/08). http://www.mhra.gov.uk/Publications/Safetywarnings/DrugAlerts/CON426907 (accessed June 30, 2014).
8. 8.↵
   MHRA Publications and Consultations, Safety Warnings, Drug Alerts. Class 2 Medicines Recall (action within 48 hours): Fybogel Orange—Reckitt Benckiser Healthcare (UK) Limited (EL (14)A/04). http://www.mhra.gov.uk/Publications/Safetywarnings/DrugAlerts/CON392875 (accessed June 30, 2014).
9. 9.↵
   MHRA Publications and Consultations, Safety Warnings, Drug Alerts. Class 2 Medicines Recall (action within 48 hours): Clarithromycin 500mg Powder for Solution for Infusion in Agila livery manufactured by Strides Arcolab International Limited (EL (14)A/07). http://www.mhra.gov.uk/Publications/Safetywarnings/DrugAlerts/CON426899 (accessed June 30, 2014).
10. 10.↵
    MHRA Publications and Consultations, Safety Warnings, Drug Alerts. Class 2 Medicines Recall (action within 48 hours): Vancomycin Powder for Concentrate for Solution for Infusion manufactured by Actavis Group PTC ehf (EL (14)A/06). http://www.mhra.gov.uk/Publications/Safetywarnings/DrugAlerts/CON425132 (accessed June 30, 2014).
11. 11.↵
    MHRA Publications and Consultations, Safety Warnings, Drug Alerts. Class 2 Medicines Recall (action within 48 hours): Viread 245 mg Film-Coated Tablets—Gilead Sciences Limited (EL (14)A/03). http://www.mhra.gov.uk/Publications/Safetywarnings/DrugAlerts/CON391205 (accessed June 30, 2014).
12. 12.↵
    U.S. Code of Federal Regulations Title 21 Part 7.3(m): Definitions. ecfr.gpoaccess.gov (accessed Sep. 2, 2014).
13. 13.↵
    1. Turco S.,
    2. Davis N.

    Glass Particles in Intravenous Injections. New Engl. J. Med. 1972, 287, 1204–1205.

    OpenUrlPubMed
14. 14.↵
    1. Dempsey G.

    Hazards of Particle Injection. Pharm. J. 1983, July 16, 63–64.
15. 15.↵
    1. Davis N. M.,
    2. Turco S.,
    3. Sivelly E.

    A Study of Particulate Matter in I.V. Infusion Fluids. Am. J. Hosp. Pharm. 1970, 27, 822–826.

    OpenUrlPubMed
16. 16.↵
    1. Backhouse C. M.,
    2. Ball P. R.,
    3. Booth S.,
    4. Kelshaw M. A.,
    5. Potter S. R.,
    6. McCollum C. N.

    Particulate Contaminants of Intravenous Medications and Infusions. J. Pharm. Pharmacol. 1987, 39, 241-245.

    OpenUrlPubMedWeb of Science
17. 17.↵
    U.S. Food and Drug Administration (FDA). Multiple product recall notifications, 2009–2012. http://www.fda.gov/Drugs/DrugSafety/DrugRecalls/default.htm (accessed March–April 2012).
18. 18.↵
    FDA Recalls, Market Withdrawals, and Safety Alerts. Bedford Laboratories Issues a Voluntary Nationwide Patient Level Recall of Acetylcysteine Solution, USP, LOT 1877093. Press release, February 2, 2012. http://www.fda.gov/Safety/Recalls/ucm290204.htm (accessed June 19, 2014).
19. 19.↵
    FDA Recalls, Market Withdrawals, & Safety Alerts. American Regent Initiates Nationwide Voluntary Recall of Methyldopate HCL Injection, USP 5 mL Single Dose Vial Due to Glass Particulates. Press release, June 6, 2011. http://www.fda.gov/Safety/Recalls/ucm258064.htm (accessed June 19, 2014).
20. 20.↵
    FDA Recalls, Market Withdrawals, and Safety Alerts. American Regent Initiates Nationwide Voluntary Recall of Caffeine & Sodium Benzoate Injection, USP 250 mg/mL, 2 mL Single Dose Vial Due to Visible Particulates. Press release, May 5, 2011. http://www.fda.gov/Safety/Recalls/ArchiveRecalls/2011/ucm254287.htm (accessed June 19, 2014).
21. 21.↵
    MHRA Publications and Consultations, Safety Warnings, Drug Alerts. Class 4 Drug Alert: B.Braun Medical Ltd—NuTRIflex Lipid Products (EL (11)A/32). http://www.mhra.gov.uk/Publications/Safetywarnings/DrugAlerts/CON137913 (accessed June 19, 2014).
22. 22.↵
    MHRA Publications and Consultations, Safety Warnings, Drug Alerts. Class 2 Drug Alert (Action within 48 hours): Abraxis BioScience Ltd—Abraxane 5mg/ml powder for suspension for infusion (EL (09)A/28). http://www.mhra.gov.uk/Publications/Safetywarnings/DrugAlerts/CON062632 (accessed June 19, 2014).
23. 23.↵
    1. Schroeder H.G.,
    2. DeLuca P.P.

    Particulate Matter Assessment of a Clinical Investigation on Filtration and Infusion Phlebitis. AJHP. 1976, 33, 543–546.

    OpenUrlPubMed
24. 24.↵
    1. Lehr H.-A.,
    2. Brunner J.,
    3. Rangoonwala R.,
    4. Kirkpatrick C. J.

    Particulate Matter Contamination of Intravenous Antibiotics Aggravates Loss of Functional Capillary Density in Postischemic Striated Muscle. Am. J. Respir. Crit. Care Med. 2002, 165, 514–520.

    OpenUrlCrossRefPubMedWeb of Science
25. 25.↵
    1. Macdougall I. C.,
    2. Roger S. D.,
    3. de Francisco A.,
    4. Goldsmith D. J. A.,
    5. Schellekens H.,
    6. Ebbers H.,
    7. Jelkmann W.,
    8. London G.,
    9. Casadevall N.,
    10. Hörl W. H.,
    11. Kemeny D. M.,
    12. Pollock C.

    Antibody-Mediated Pure Red Cell Aplasia in Chronic Kidney Disease Patients Receiving Erythropoiesis-Stimulating Agents: New Insights. Kidney Int. 2012, 81 (8), 727–732.

    OpenUrlCrossRefPubMedWeb of Science
26. 26.↵
    1. Singh K. S.

    Impact of Product-Related Factors on Immunogenicity of Biotherapeutics. J. Pharm. Sci. 2011, 100, 354–387.

    OpenUrlCrossRefPubMed
27. 27.↵
    1. Carpenter J. F.,
    2. Randolph T. W.,
    3. Jiskoot W.,
    4. Crommelin D, J.,
    5. Middaugh R. C.,
    6. Winter G.,
    7. Fan Y.-X.,
    8. Kirshner S.,
    9. Verthely I, D.,
    10. Kozlowski S.,
    11. Clouse K. A.,
    12. Swann P. G.,
    13. Roseberg A.,
    14. Cherney B.

    Overlooking Subvisible Particles in Therapeutic Protein Products: Gaps That May Compromise Product Quality. J. Pharm. Sci. 2009, 98 (4), 1201–1205.

    OpenUrlCrossRefPubMed
28. 28.↵
    1. Watson R.,
    2. Strab J.

    Manual Inspection Capability to Detect Particulate in Parenterals. Presented at the 2013 PDA Visual Inspection Forum, Oct 7–8, 2013, Bethesda, MD.
29. 29.↵
    1. Brewer J. H.,
    2. Dunning J. H. F.

    An In Vitro and In Vivo Study of Glass Particles in Ampules. J. Am. Pharm. Assoc. 1947, 36 (10), 289–293.

    OpenUrl
30. 30.↵
    1. Stehbens W.E.,
    2. Florey H.W.

    The Behaviour of Intravenously Injected Particles Observed in Chambers in Rabbits' Ears. Q.J. Exp. Physiol. 1960, 45, 252–264.

    OpenUrl
31. 31.↵
    1. Schoenberg M.D.,
    2. Gilman P.A.,
    3. Mumaw V.R.,
    4. Moore R.D.

    The Phagocytosis of Uniform Polystyrene Latex Particles (PLP) by the Reticulo-Endothelial System (RES) in the Rabbit. Brit. J. Exp. Pathol. 1961, 42 (5), 486–495.

    OpenUrlPubMedWeb of Science
32. 32.↵
    General Chapter <1> Injections. USP 36/NF 31; U.S. Pharmacopeia: 2013. www.usp.org.
33. 33.↵
    Chapter 2.9.20, Particulate Contamination: Visible Particles; European Pharmacopeia: 2013.
34. 34.↵
    Eudralex, Guideline on Production and Quality Control of Monoclonal Antibodies and Related Substances; European Commission: 2007. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003073.pdf (accessed July 9, 2014).
35. 35.↵
    Chapter 6.06, Foreign Insoluble Matter Test for Injections; Japanese Pharmacopeia: 2011 http://db.yaozh.com/foreign/JP15/jp1/F1_70.pdf (accessed July 9, 2014).
36. 36.↵
    1. Knapp J. Z,
    2. Kushner H. R.

    Generalized Methodology for Evaluation of Parenteral Inspection Procedures. PDA J. Pharm. Sci. Tech. 1980, 34 (1), 14–61.

    OpenUrl
37. 37.↵
    1. Knapp J. Z,
    2. Kushner H. R.

    Implementation and Automation of a Particle Detection System for Parenteral Products. PDA J. Pharm. Sci. Tech. 1980, 34 (5), 369–393.

    OpenUrl
38. 38.↵
    1. Shabushnig J. G.,
    2. Melchore J. A.,
    3. Geiger M.,
    4. Chrai S.,
    5. Gerger M. E.

    A Proposed Working Standard for Validation of Particulate Inspection in Sterile Solutions. Paper presented at the PDA Annual Meeting, Philadelphia, November 2–4, 1995.
39. 39.
    General Chapter <788> Particulate Matter in Injections; USP 37/NF 32; U.S. Pharmacopeia: 2011. www.usp.org.
40. 40.↵
    Monograph for Monoclonal Antibodies for Human Use; European Pharmacopeia: 2013.
41. 41.↵
    Circulaire N°10-0224 Direction Des Affaires Scientifiques, Pharmaceutiques Et Medicales AFSSAPS Form n° 2 – Complaints “glass particles in injectable products,” (Notification of “glass particles in injectable products”) April 19, 2010.
42. 42.↵
    1. Mirtallo J.,
    2. Canada T.,
    3. Johnson D.,
    4. Kumpf V.,
    5. Petersen C.,
    6. Sacks G.,
    7. Seres D.,
    8. Guenter P.

    Special Report: Safe Practices for Parenteral Nutrition. JPEN J. Parenter. Enteral Nutr. 2004, 28 (6), S39–S70.

    OpenUrlFREE Full Text
43. 43.↵
    1. Thomas W. H.,
    2. Lee Y. K.

    Particles in Intravenous Solutions: A Review. New Zeal. Med. J. 1974, 80, 170–178.

    OpenUrlPubMed
44. 44.↵
    1. Borchert S. J.,
    2. Abe A.,
    3. Aldrich S. D.,
    4. Fox L. E.,
    5. Freeman J. E.,
    6. White R. D.

    Particulate Matter in Parenteral Products: A Review. PDA J. Pharm. Sci. Tech. 1986, 40 (5), 212–241.

    OpenUrl
45. 45.↵
    1. Groves M. J.,
    2. De Malka S. R.

    The Relevance of Pharmacopeial Particulate Matter Tests. Drug Development Communications, 1976, 2, 285–324.

    OpenUrl
46. 46.↵
    1. Groves M. J.

    Parenteral Products: The Preparation and Quality Control of Products for Injection; William Heinemann Medical Books: London, 1973.
47. 47.↵
    1. Groves M. J.

    Particulate Matter: Sources and Resources for Healthcare Manufacturers; Interpharm Press: Buffalo Grove, IL, 1993.
48. 48.↵
    1. Langille S. E.

    Particulate Matter in Injectable Drug Products. PDA J. Pharm. Sci. Tech. 2013, 67, 186–200.

    OpenUrl
49. 49.↵
    1. Xie Guangping,
    2. Sun Jiao,
    3. Zhong Gaoren,
    4. Shi Liyi,
    5. Zhang Dawei.

    Biodistribution and Toxicity of Intravenously Administered Silica Nanoparticles in Mice. Arch Toxicol. 2010, 84, 183–190.

    OpenUrlCrossRefPubMed
50. 50.↵
    1. Cho M.,
    2. Cho W.-S.,
    3. Choi M.,
    4. Kim S. J.,
    5. Han B. S.,
    6. Kim S. H.,
    7. Kim H. O.,
    8. Sheen Y. Y.,
    9. Jeong J.

    The Impact of Size on Tissue Distribution and Elimination by Single Intravenous Injection of Silica Nanoparticles. Toxicol Lett. 2009, 189, 177-183.

    OpenUrlCrossRefPubMedWeb of Science
51. 51.↵
    1. Hozumi K.,
    2. Kitamura K.,
    3. Kitade T.,
    4. Iwagami S.

    Localization of Glass Particles in Animal Organs Derived from Cutting of Glass Ampoules Before Intravenous Injections. Microchem. J. 1983, 28, 215–226.

    OpenUrl
52. 52.↵
    1. Hay J.

    Complications at Site of Injection of Depot Neuroleptics. BMJ 1995, 311, 421.

    OpenUrlFREE Full Text
53. 53.↵
    1. Miliauskas J. R.,
    2. Mukherjee T.,
    3. Dixon. B.

    Postimmunization (Vaccination) Injection-Site Reactions: A Report of Four Cases and Review of the Literature. Am. J. Surg. Pathol. 1993, 17 (5), 516–524.

    OpenUrlPubMedWeb of Science
54. 54.↵
    1. Greenblatt D.,
    2. Divoll-Allen M.

    Intramuscular Injection-Site Complications. JAMA 1978, 240 (6), 542–544.

    OpenUrlCrossRefPubMedWeb of Science
55. 55.↵
    1. Drews R.C.

    Use of Millipore Filters in Ophthalmic Surgery. Am J Ophthalmol. 1960, 50, 159–160.

    OpenUrlPubMed
56. 56.↵
    1. Pinnock C. A.

    Particulate Contamination of Solutions for Intrathecal Use. Ann. R. Coll. Surg. Engl. 1984, 66 (6), 423.

    OpenUrlPubMed
57. 57.↵
    1. Akers M. J.,
    2. Larrimore D. S.,
    3. Guazzo D. M.

    Parenteral Quality Control: Sterility, Pyrogen, Particulate, and Package Integrity Testing. Marcel Dekker: New York, 1994; p. 179.
58. 58.↵
    1. Niden A. H.,
    2. Aviado D. M.

    Effects of Pulmonary Embolism on the Pulmonary Circulation with Special Reference to Arteriovenous Shunts in the Lungs Circulation Res. 1956, 4, 67–73.

    OpenUrlAbstract/FREE Full Text
59. 59.↵
    1. Groom R. C.,
    2. Quinn R. D.,
    3. Lennon P.,
    4. Donegan D. J.,
    5. Braxton J. H.,
    6. Kramer R. S.,
    7. Weldner P. W.,
    8. Russo L.,
    9. Blank S. D.,
    10. Christie A. A.,
    11. Taenzer A. H.,
    12. Forest R. J.,
    13. Clark C.,
    14. Welch J.,
    15. Ross C. S.,
    16. O'Connor G. T.,
    17. Likosky D. S.

    Detection and Elimination of Microemboli Related to Cardiopulmonary Bypass. Circ. Cardiovasc. Qual. Outcomes 2009, 2, 191–198.

    OpenUrlAbstract/FREE Full Text
60. 60.↵
    1. Blauth C. I.

    Macroemboli and Microemboli During Cardiopulmonary Bypass. Ann. Thorac. Surg. 1995, 59, 1300–1303.

    OpenUrlCrossRefPubMedWeb of Science
61. 61.↵
    1. Stump D. A.,
    2. Rogers A. T.,
    3. Hammon J. W.,
    4. Newman S. P.

    Cerebral Emboli and Cognitive Outcome After Cardiac Surgery. J. Cardiothorac. Vasc. Anesth. 1996, 10 (1), 113–119.

    OpenUrlCrossRefPubMedWeb of Science
62. 62.↵
    1. Liu Y.-H.,
    2. Wang D.-X.,
    3. Li L.-H.,
    4. Wu X.-M.,
    5. Shan G.-J.,
    6. Su Y.,
    7. Li J.,
    8. Yu Q.-J.,
    9. Shi C.-X.,
    10. Huang Y.-N.,
    11. Sun W.

    The Effects of Cardiopulmonary Bypass on the Number of Cerebral Microemboli and the Incidence of Cognitive Dysfunction After Coronary Artery Bypass Graft Surgery. Anesth. Analg. 2009, 109 (4), 1013–1022.

    OpenUrlCrossRefPubMedWeb of Science
63. 63.↵
    1. Liu J.-F.,
    2. Su Z.-K.,
    3. Ding W.-X.

    Quantitation of Particulate Microemboli During Cardiopulmonary Bypass: Experimental and Clinical Studies. Ann. Thorac. Surg. 1992, 54, 1196–1202.

    OpenUrlCrossRefPubMedWeb of Science
64. 64.↵
    1. Schoenberg M. D.,
    2. Gilman P. A.,
    3. Mumaw V.,
    4. Moore R. D.

    Proliferation of the Reticuloendothelial System and Phagocytosis. Exp. Mol. Pathol. 1962, 2, 126–143.

    OpenUrl
65. 65.↵
    1. Brekkan A.,
    2. Lexow P. E.,
    3. Woxholt G.

    Glass Fragments and Other Particles Contaminatng [sic] Contrast Media. Acta Radiol.: Diagnosis, 1975, 16 (6), 600–608.

    OpenUrl
66. 66.↵
    1. Walpot H.,
    2. Frank R. P.,
    3. Burchard W. G.,
    4. Agternkamp C.,
    5. Müller F. G.,
    6. Mittermayer C.,
    7. Kalff G.

    Particulate Contamination of Intravenous Solutions and Drug Additives During Long-Term Intensive Care. Anaesthesist, 1989, 38, 617–621.

    OpenUrlPubMed
67. 67.↵
    1. Jones M. L.,
    2. Warren J. S.

    Monocyte Chemoattractant Protein 1 in a Rat Model of Pulmonary Granulomatosis. Laboratory Investigation 1992, 66 (4), 498–503.

    OpenUrlPubMedWeb of Science
68. 68.↵
    1. Bautista A. P.,
    2. Schuler A.,
    3. Spolarics Z.,
    4. Spitzer J. J.

    In Vivo Latex Phagocytosis Primes the Kupffer Cells and Hepatic Neutrophils to Generate Superoxide Anion. J. Leukoc. Biol. 1992, 51, 39–45.

    OpenUrlAbstract
69. 69.↵
    1. Garvan J. M.,
    2. Gunner B. W.

    The Harmful Effects of Particles in Intravenous Fluids. Med. J. Aust. 1964, 2 (1), 1–6.

    OpenUrlPubMedWeb of Science
70. 70.↵
    1. Garvan J. M.,
    2. Gunner B.W.

    Intravenous Fluids: “A Solution Containing Such Particles Must Not Be Used.” Med. J. Aust. 1963, 2, 140–145.

    OpenUrl
71. 71.↵
    1. Hill S. E.,
    2. Heldman L. S.,
    3. Goo E. D. H.,
    4. Whippo P. E.,
    5. Perkinson J. C.

    Fatal Microvascular Pulmonary Emboli from Precipitation of a Total Nutrient Admixture Solution. JPEN J. Parenter. Enteral Nutr. 1996, 20 (1), 81–86.

    OpenUrlAbstract/FREE Full Text
72. 72.↵
    1. Reedy J. S.,
    2. Kuhlman J. E.,
    3. Voytovich M.

    Microvascular Pulmonary Emboli Secondary to Precipitated Crystals in a Patient Receiving Total Parenteral Nutrition: A Case Report and Description of the High-Resolution CT Findings. Chest 1999, 115, 892–895.

    OpenUrlCrossRefPubMedWeb of Science
73. 73.↵
    1. Burton J. F.,
    2. Zawadzki E. S.,
    3. Wetherell H. R.,
    4. Moy T. W.

    Mainliners and Blue Velvet. Paper presented at 17th Annual Meeting of the American Academy of Forensic Sciences, Chicago, February 25, 1965.
74. 74.↵
    1. Douglas F. G.,
    2. Kafilmount K. J.,
    3. Patt N. L.

    Foreign Particle Embolism in Drug Addicts: Respiratory Pathophysiology. Ann. Intern. Med. 1971, 75 (6), 865–872.

    OpenUrlPubMedWeb of Science
75. 75.↵
    1. Jones B. S.,
    2. Brancaccio F. A.,
    3. Rodriguez G. A.

    Dyspnea and Bilateral Interstitial Pulmonary Infiltrates in an Intravenous Drug User. Proc. (Bayl. Univ. Med. Cent.) 2002, 15, 430–432.

    OpenUrlPubMed
76. 76.↵
    1. Richman H. S.

    Acute Pulmonary Edema Associated with Librium Abuse. Radiology, 1972, 103, 57–58.

    OpenUrlCrossRefPubMed
77. 77.↵
    1. Jorens P. G.,
    2. Van Marck E.,
    3. Snoeckx A.,
    4. Parizel P. M.

    Nonthrombotic Pulmonary Embolism. Eur. Respir. J. 2009, 34, 452–474.

    OpenUrlAbstract/FREE Full Text
78. 78.↵
    1. Kringsholm B.,
    2. Christoffersen P.

    The Nature and the Occurrence of Birefringent Material in Different Organs in Fatal Drug Addiction. Forensic Sci. Int. 1987, 34, 53–62.

    OpenUrlCrossRefPubMedWeb of Science
79. 79.↵
    1. Baydur A.,
    2. Koss M. N.,
    3. Sharma O. P.,
    4. Dalgleish G. E.,
    5. Nguyen D. V.,
    6. Mullick F. G.,
    7. Murakata L. A.,
    8. Centeno J. A.

    Microscopic Pulmonary Embolisation of an Indwelling Central Venous Catheter with Granulomatous Inflammatory Response. Eur. Respir. J. 2005, 26, 351–353.

    OpenUrlAbstract/FREE Full Text
80. 80.↵
    1. Wijeyaratne S. M.,
    2. Ubayasiri R. A.,
    3. Weerasinghe C.

    Fatal Pulmonary Embolism of Polyvinyl Alcohol Particles Following Therapeutic Embolisation of a Peripheral Arteriovenous Malformation. BMJ Case Reports. http://casereports.bmj.com/content/2009/bcr.02.2009.1635.full?sid=c744e316-4da4-4584-8d8e-1dd9ba2ca9e3 (accessed March 12, 2014).
81. 81.↵
    1. Brown K. T.

    Fatal pulmonary complications after arterial embolization with 40–120-μm tris-acryl gelatin microspheres. J Vasc Interv Radiol. 2004, 15 (2), 197–200.

    OpenUrlPubMedWeb of Science
82. 82.↵
    1. Plasencia A. R.,
    2. Santillan A.

    Embolization and Radiosurgery for Arteriovenous Malformations. Surg Neurol Int. 2012, 2 (Supple 2), S90–S104.

    OpenUrl
83. 83.↵
    1. Mahler H.-C.,
    2. Friess W.,
    3. Grauschopf U.,
    4. Kiese S.

    Protein Aggregation: Pathways, Induction Factors and Analysis. J. Pharm. Sci. 2009, 98 (9), 2909–2934.

    OpenUrlCrossRefPubMed
84. 84.↵
    1. Narhi L. O.,
    2. Jiang Y.,
    3. Cao S.,
    4. Benedek K.,
    5. Shnek D.

    A Critical Review of Analytical Methods for Subvisible and Visible Particles. Curr. Pharm. Biotechnol. 2009, 10 (4), 373–381.

    OpenUrlCrossRefPubMed
85. 85.↵
    1. Sharma D. K.,
    2. King D.,
    3. Oma P.,
    4. Merchant C.

    Micro-Flow Imaging: Flow Microscopy Applied to Sub-visible Particulate Analysis in Protein Formulations. AAPS J. 2010, 12 (3), 455–464.

    OpenUrlPubMed
86. 86.↵
    1. Gentile F.,
    2. Curcio A.,
    3. Indolfi C.,
    4. Ferrari M.,
    5. Decuzzi P.

    The Margination Propensity of Spherical Particles for Vascular Targeting in the Microcirculation. J. Nanobiotechnology 2008, 6 (9), 1–9.

    OpenUrlPubMed
87. 87.↵
    1. Shannon P.,
    2. Billbao J.M.,
    3. Marotta T.,
    4. Terbrugge K.

    Inadvertent Foreign Body Embolization in Diagnostic and Therapeutic Cerebral Angiography. Am J. Neuroradiol. 2006, 27, 278–282.

    OpenUrlAbstract/FREE Full Text
88. 88.↵
    Technical Report No 44: Quality Risk Management for Aseptic Processes; Parenteral Drug Association: 2008. https://store.pda.org/ProductCatalog/Product.aspx?ID=1220 (Accessed July 21, 2014).
89. 89.↵
    Quality Guideline Q9: Quality Risk Management; International Conference on Harmionisation: 2005. www.ich.org (accessed March 11, 2014).
90. 90.↵
    1. Newton D. W.,
    2. Driscoll D. F.

    Calcium and Phosphate Compatibility: Revisited Again. Am. J. Health Syst. Pharm. 2008, 65, 73–80.

    OpenUrlFREE Full Text
91. 91.↵
    1. Allcutt D. A.,
    2. Lort D.,
    3. McCollum C. N.

    Final Inline Filtration for Intravenous Infusions: A Prospective Hospital Study. Br. J. Surg. 1983, 70, 111–113.

    OpenUrlPubMedWeb of Science
92. 92.↵
    1. Kweder S.

    Deputy director, Office of New Drug Development, FDA. Presentation to U.S. Senate Committee on Health, Education, Labor, and Pensions, December 15, 2011.
93. 93.↵
    1. Parikh M. J.,
    2. Dumas G.,
    3. Silvestri A.,
    4. Bistrian B. R.,
    5. Driscoll D. F.

    Physical Compatibility of Neomatal Total Parenteral Nutrient Admixtures Containing Organic Calcium and Inorganic Phosphate Salts. Am. J. Health Syst. Pharm. 2005, 62, 1177–1183.

    OpenUrlAbstract/FREE Full Text